Updates in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma from ASH 2021

Experts review key updates in multiple myeloma management from the ASH 2021 annual meeting.

EP. 1: Treatment Options for Patients With MM at First Relapse

January 25th 2022

Expert perspective on the management of multiple myeloma at first relapse in the context of recent clinical data from the ASH 2021 Annual Meeting.

EP. 2: A Role for Bispecific Antibodies in R/R MM: Data From MonumenTAL-1 and MajesTEC-1 Studies

January 25th 2022

Insight on results from the MonumenTAL-1 and MajesTEC-1 studies, which evaluated bispecific antibodies in patients with relapsed/refractory multiple myeloma.

EP. 3: How Will Bispecific Antibodies Fit Into the Multiple Myeloma Treatment Paradigm?

January 25th 2022

Amrita Y. Krishnan, MD, considers where bispecific antibodies will fit into the multiple myeloma treatment paradigms as single-agent or combination therapy.

EP. 4: Key Takeaways From the ASH 2021 Meeting on Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

January 25th 2022

Closing out her discussion on the management of newly diagnosed and relapsed/refractory multiple myeloma, Amrita Y. Krishnan, MD, shares key takeaways from the ASH 2021 Annual Meeting.

EP. 5: Transplant-Eligible NDMM: Updated Results of the GRIFFIN Study

February 4th 2022

Updated results from the GRIFFIN study, which combined daratumumab with RVd in patients with transplant-eligible newly diagnosed multiple myeloma.

EP. 6: Transplant-Eligible NDMM: Results From the MASTER Study

February 4th 2022

Expert perspective on results from the MASTER study analyzing daratumumab in combination with KRd in transplant-eligible newly diagnosed multiple myeloma.

EP. 7: Triplet or Quadruplet Therapy in Transplant-Ineligible NDMM

February 4th 2022

In the context of transplant-ineligible newly diagnosed multiple myeloma, Saad Usmani, MD, considers the role of triplet versus quadruplet therapy.

EP. 8: Daratumumab in NDMM: Subcutaneous vs IV Formulation

February 4th 2022

Closing out his discussion on newly diagnosed multiple myeloma, Saad Usmani, MD, considers the approval and use of subcutaneous daratumumab.

EP. 9: Relapsed/Refractory MM: Results From the BELLINI Study

February 4th 2022

Insight on the BELLINI study, which added venetoclax to bortezomib and dexamethasone for patients with relapsed/refractory multiple myeloma.

EP. 10: Adding Venetoclax to Daratumumab and Dexamethasone in RRMM

February 4th 2022

In relapsed/refractory multiple myeloma, a recent study tested the addition of venetoclax to daratumumab and dexamethasone.